This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BREEZE 3 Data For Serada® Presented At 2012 North American Menopause Society Annual Meeting

MENLO PARK, Calif., Oct. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today that it is presenting two abstracts from its Phase 3 clinical trial, BREEZE 3, at this week's 23 rd Annual Meeting of the North American Menopause Society (NAMS) in Orlando, FL.  The data showed that Serada ®, Depomed's investigational non-hormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes.

(Logo: http://photos.prnewswire.com/prnh/20121003/NY85857LOGO )

"Hot flashes are a disruptive problem affecting as many as three out of four menopausal women," said JoAnn V. Pinkerton, M.D., principal investigator of BREEZE 3 and Medical Director of Midlife Health Center, Professor of Obstetrics and Gynecology and Vice Chair of Academic Affairs at the University of Virginia, Charlottesville.  "At this time, hormone therapy is the only approved treatment for hot flashes, yet about 40% of symptomatic women either choose not to go on hormones or are not good candidates.   The BREEZE 3 data findings are important news for women who are looking for more choices to manage their hot flashes and the sleep issues that often accompany them."

BREEZE 3 Statistical Analyses - Non-parametric Analysis vs. ANCOVA Parametric Analysis.  The BREEZE 3 study included 600 menopausal women who were treated with either Serada 1800mg daily (given as one 600mg tablet in the morning and two 600mg tablets at night) or placebo for 24 weeks.  Depomed entered into a Special Protocol Assessment with the FDA with respect to the BREEZE 3 study that specified Depomed would use a non-parametric analysis for the efficacy data from BREEZE 3, and would also perform a supportive parametric ANCOVA statistical analysis.  As previously disclosed, based on the primary non-parametric analysis, efficacy data from the trial were positive and statistically significant for three of the four pre-specified primary endpoints of frequency and severity of hot flashes at four and 12 weeks.  Data for the key secondary endpoints of frequency and severity at 24 weeks did not achieve statistical significance.

The results of the supportive ANCOVA parametric analysis of the BREEZE 3 data were presented at NAMS. In this analysis, Serada significantly reduced the frequency and severity of hot flashes at 4 weeks and 12 weeks compared with placebo.  These reductions were maintained out to 24 weeks.  In addition, an assessment of sleep measures taken at the start of the trial indicated that, on average, women had clinically meaningful improvements in insomnia and sleep disturbance. 

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs